Free Trial

Mangoceuticals Q4 2024 Earnings Report

Mangoceuticals logo
$1.84 -0.17 (-8.46%)
As of 04/4/2025 04:00 PM Eastern

Mangoceuticals EPS Results

Actual EPS
-$1.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Mangoceuticals Revenue Results

Actual Revenue
$0.11 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mangoceuticals Announcement Details

Quarter
Q4 2024
Time
After Market Closes

Conference Call Resources

Remove Ads

Mangoceuticals Earnings Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Mangoceuticals launches PeachesRx women’s telehealth brand
See More Mangoceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mangoceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mangoceuticals and other key companies, straight to your email.

About Mangoceuticals

Mangoceuticals (NASDAQ:MGRX) develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

View Mangoceuticals Profile

More Earnings Resources from MarketBeat